Global Neurological Biomarkers Market to reach USD 14.3 billion by 2027.Global Neurological Biomarkers Market is valued approximately USD 6.1 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 12.9% over the forecast period 2021-2027. Alzheimer's disease and Parkinson's disease are neurodegenerative illnesses that cause progressive loss of cognitive function, dementia, and movement difficulties. The rise in the incidence of neurological diseases such as migraines, dementia, Alzheimer's disease, brain tumours, and epilepsy can be contributed to the market's expansion. Furthermore, technological advances and the growing demand for early detection of neurological diseases are driving the market growth. In 2019, according to the WHO (World Health Organization), epilepsy accounted for about 13 million disability-adjusted lifespan and more than 0.5 percent of the global burden of illness. The market is projected to expand as the number of instances of Alzheimer's disease among the elderly population rises. However, the market is expected to be hampered by the adoption of strict government rules for the authorization of commercial use of biomarkers, as well as increasing ethical problems surrounding early detection of Alzheimer's and Parkinson's diseases. Whereas, the growth in demand for customized medicine is expected to provide opportunities for neurological biomarker market growth in forecasting years.


The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical analysis of the worldwide Neurological Biomarkers market. North America held the largest market share in 2020 and is anticipated to expand at a significant CAGR throughout the forecast period. The region's dominance is due to a considerable rise in illness burden, adoption of biomarkers for diagnostic, therapeutic development, and prognostic reasons, and increased research funding. Furthermore, in forecasting years, Asia Pacific is anticipated to expand at the fastest CAGR. The Asia Pacific region is projected to be driven by an increase in the number of clinical trials undertaken in emerging nations such as India and China, increased illness burden, and growing demand for targeted medicines in the central nervous system.

Major market player included in this report are:
Abbott Laboratories
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Banyan Biomarkers, Inc.
Myriad Genetics, Inc.
DiaGenic ASA
Quanterix
Myriad RBM
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Application:
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others
By Type:
Genomic
Proteomic
Metabolomic
Imaging
Others
By End-use:
Hospital & Hospital Laboratories
Independent Clinical Diagnostic Centers
Research Organizations and Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Neurological Biomarkers Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors